ArticleBreast cancer research and treatment2018
Breast cancer survival, survival disparities, and guideline-based treatment.
Article in Breast cancer research and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 53 citations in OpenAlex.
- Associations Between Acculturation and Weight, Diet Quality, and Physical Activity Among Latina Breast Cancer Survivors: The ¡Mi Vida Saludable! Study.Journal of the Academy of Nutrition and Dietetics · 2022Trial
- Real-World Mapping of Multiple Primary Carcinoma Combinations and Survival Outcomes in Shanghai, China: Retrospective Registry-Based Study.JMIR public health and surveillance · 2026Article
- Plexin A2 regulated the metastasis in breast cancer through MCM7.BMC cancer · 2026Article
- Association of health literacy with cancer survival: a single-centre prospective cohort study.Acta oncologica (Stockholm, Sweden) · 2025Article
- Receipt of guideline-concordant care and survival among young adult women with non-metastatic breast cancer.Breast cancer research and treatment · 2025Article
- Article
- Are there differences in overall survival among older breast cancer patients by race and ethnicity?Surgery · 2025Article
- Expression characteristics, molecular mechanisms, and clinical significance of DICER1 in breast cancer.Frontiers in genetics · 2025Article
- Cardiovascular comorbidities and cancer-directed therapies in Hispanic breast cancer patients: a two-center analysis from the Southwestern U.S.Frontiers in oncology · 2025Article
- The Safety and Efficacy of Anticancer Therapy in Breast Cancer Patients with Liver Cirrhosis.Cancer management and research · 2025Article
- Comparison of surgical margins and adjuvant therapy for head and neck cancer by hospital type.Translational cancer research · 2024Article
- Understanding Benign Breast Disease and Subsequent Breast Cancer in Hispanic White Females: A Step Closer to Evidence-Based Management.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Observational
- Small molecule agents for triple negative breast cancer: Current status and future prospects.Translational oncology · 2024Review
- Overexpression of Long Non-coding RNA uc.246 Facilitates Angiogenesis, Migration, and EMT Phenotype of Human Breast Cancer Cells.Applied biochemistry and biotechnology · 2024Article
- Obstetric and perinatal outcomes in women with previous breast cancer: a nationwide study of singleton births 1973-2017.Human reproduction open · 2024Article
- A comprehensive analysis of the prognostic characteristics of microRNAs in breast cancer.Frontiers in genetics · 2024Article
- CCDC3 Gene Regulates the Proliferation of Breast Cancer Cells.Bulletin of experimental biology and medicine · 2023Article
- Breast cancer survival and the health system in Brazil: an analysis of public and private healthcare.Frontiers in oncology · 2023Article
- Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers.Frontiers in endocrinology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
purposeThe role of appropriate therapy in breast cancer survival and survival disparities by race/ethnicity has not been fully elucidated. We investigated whether lack of guideline-recommended therapy contributed to survival differences overall and among Hispanics relative to non-Hispanic white (NHW) women in a case-cohort study.
methodsThe study included a 15% random sample of female invasive breast cancer patients diagnosed from 1997 to 2009 in 6 New Mexico counties and all deaths due to breast cancer-related causes. Information was obtained from comprehensive medical chart reviews. National Comprehensive Cancer Network (NCCN®) guideline-recommended treatment was assessed among white women aged < 70 who were free of contraindications for recommended therapy, had stage I-III tumors, and survived ≥ 12 months. Hazard ratios (HRs) and 95% confidence intervals (CIs) for breast cancer death were estimated using Cox proportional hazards models.
resultsIncluded women represented 4635 patients and 449 breast cancer deaths. Women who did not receive radiotherapy (HR 2.3; 95% CI 1.2-4.4) or endocrine therapy (HR 2.0; 95% CI 1.0-4.0) as recommended by guidelines had an increased risk of breast cancer death, relative to those treated appropriately. Receipt of guideline-recommended therapy did not differ between Hispanic and NHW women for chemotherapy (84.2% vs. 81.3%, respectively), radiotherapy (89.2% vs. 91.1%), or endocrine therapy (89.2% vs. 85.8%), thus did not influence Hispanic survival disparities.
conclusionsLack of guideline-recommended radiotherapy or endocrine therapy contributed to survival as strongly as other established prognostic indicators. Hispanic survival disparities in this population do not appear to be attributable to treatment differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.